Key facts
- It has raised $1.1M; the latest was Angel (individual) ($1.1M) in Jan 2026.
- Notable investors include Incubateur HEC Paris, Agrinove, Animal Health Angels, Circle of Veterinary Investors, Groupe Cristal — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for BioAZ
- ·The full record, as it builds
Funding rounds
No funding rounds for BioAZ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioAZ
Operator of a biotechnology venture intended to advance animal health through ethical and sustainable immunotherapies. The company offers biotechnology-driven immunotherapies that are practical to administer and considerate of animal welfare, enabling farmers, veterinarians, and veterinary pharmaceutical partners to support healthier animals with approaches aligned to sustainable farming.
- Sector
- Business Products and Services (B2B)
- HQ
- Maransin, France
- Founded
- 2022
- Employees
- 4
- Website
- bioaz.vet/
- Ownership
- Privately Held (backing)
BioAZ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioAZ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioAZ in its N-PORT filings yet. We sweep new filings monthly.